Table 3 The association of uEGF with time to composite end point.

The association was evaluated by a Cox proportional hazards regression analysis in C-PROBE, NEPTUNE, and PKU-IgAN cohorts. Renal event is defined as the presence of composite end point of ESKD or 40% reduction in baseline eGFR. The follow-up lengths (in years) for this analysis for the three cohorts were 1.8 ± 0.8, 2.0 ± 0.8, and 3.6 ± 2.2, respectively. AIC, Akaike information criterion; LR, likelihood ratio test.

CohortModelAICC-statisticsP value (LR test)
C-PROBE (25 events/189 patients)
M1eGFR + ACR*206.30.75 (0.58–0.91)
M2eGFR + ACR* + EGF192.10.87 (0.77–0.97)<0.0001
NEPTUNE (26 events/110 patients)
M1eGFR + ACR*213.980.74 (0.61–0.86)
M2eGFR + ACR* + EGF204.140.80 (0.68–0.92)0.0006
PKU-IgAN (68 events/428 patients)
M1eGFR + ACR*660.180.71 (0.59–0.83)
M2eGFR + ACR* + EGF647.940.75 (0.64–0.86)0.00016

*Adjusted for age and gender.